Document:

Amendment No. 2 to Promissory Note

 Exhibit 10.1 

EXECUTION VERSION 
 AMENDMENT NO.
2 TO PROMISSORY NOTE 
 This Amendment No. 2 to Promissory Note (this “Amendment”), dated as of October 1,
2015, is entered into by and among Odyssey Marine Enterprises, Ltd., a Bahamas company (the “Company”), whose address is Lyford Financial Centre, Lyford Cay, P.O. Box N-7776, Nassau, Bahamas, Odyssey Marine Exploration, Inc., a
Nevada corporation (the “Guarantor”), and Minera del Norte, S.A. de C.V. (the “Lender”). Capitalized terms used in this Amendment but not otherwise defined herein shall have the respective meanings ascribed to them
in the Promissory Note (as defined below). 
 R E C I T A L S: 

WHEREAS, the Company, the Guarantor and the Lender entered into that certain Promissory Note, dated as of March 11, 2015 (as amended by
Amendment No. 1 thereto dated as of April 10, 2015, and in effect as of the date hereof, the “Promissory Note”); 

WHEREAS, the Lender remains the Holder of the Promissory Note; and 

WHEREAS, the Company, Guarantor and the Lender desire to amend the Promissory Note as provided herein. 

NOW THEREFORE, in consideration of the foregoing and the mutual covenants, and agreements hereinafter set forth, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 

1. Section 2(a). Section 2(a) of the Promissory Note is hereby amended by deleting it in its entirety and inserting the following in lieu
thereof: 
 “(a) Unless otherwise converted as provided herein, the Adjusted Principal Balance shall be due and payable
in full upon written demand by the Lender; provided that the Lender agrees that it shall not demand payment of the Adjusted Principal Balance earlier than the first to occur of: (i) 30 days after the date on which (x) SEMARNAT makes a
determination with respect to the current application for the Manifestacion de Impacto Ambiental relating to the Don Diego Project, which determination is other than an approval or (y) the Company or any of its affiliates withdraws such
application without the Lender’s prior written consent; (ii) termination by Odyssey Marine Exploration, Inc. of the Stock Purchase Agreement; (iii) the occurrence of an Event of Default; (iv) December 31, 2015; or
(v) if and only if the Investor shall have terminated the Stock Purchase Agreement pursuant to Section 8.1(d)(iii) thereof, March 30, 2016 (the date of such demand being the “Maturity Date”).” 

2. Section 3(m). Section 3(m) of the Promissory Note is hereby amended by deleting the period at the end thereof, and adding the following:

 “; or (iv) any breach of Section 5(i) or (j) shall occur.” 

 3. Section 5. Section 5 of the Promissory Note is hereby amended by adding the following new
clauses immediately after clause (h) of Section 5: 
 “(i) Prepayment of Other Debt. Neither the
Company, the Guarantor nor any of their respective Subsidiaries shall prepay any Debt thereof so long as any portion of the Adjusted Principal Balance hereunder is outstanding, it being understood that this Section 5(i) shall not restrict the
ability to pay Debt at its stated maturity as in effect on the date hereof. 
 (j) Granting of Encumbrances. Neither
the Company, the Guarantor nor any of their respective Subsidiaries shall grant any Encumbrance on any property or asset thereof.” 
 4.
Release. In consideration of, among other things, Lender’s execution and delivery of this Amendment, each of the Releasors hereby forever agrees and covenants not to sue or prosecute against the Releasees and hereby forever waives,
releases and discharges each Releasee from, any and all Claims that such Releasor now has or hereafter may have, of whatsoever nature and kind, whether known or unknown, whether arising at law or in equity, against the Releasees, based in whole or
in part on facts whether or not now known, existing on or before September 30, 2015, that relate to, arise out of or otherwise are in connection with this Amendment, the Promissory Note, the Stock Purchase Agreement or any transactions
contemplated hereby, thereby or any acts or omissions in connection therewith or the negotiation thereof, provided, however, that the foregoing shall not release the “Investor” and “Guarantor” (as such terms are defined in the
Stock Purchase Agreement) from the express obligations of either under the Stock Purchase Agreement arising on or after October 1, 2015. The provisions of this Section 5 shall survive the repayment of the Promissory Note. 

5. Representation and Warranties. The Company represents and warrants that the representations and warranties set forth in Section 4 of the
Promissory Note are true and correct as of the date hereof, as if made as of the date hereof, except to the extent such representations and warranties expressly relate to an earlier date, in which case as of such earlier date. The Company and the
Guarantor hereby represent and warrant to the Lender that this Amendment (a) has been duly authorized by the board of directors, or similar governing body, of the Company and the Guarantor, including by the approval of a majority of the
directors of the Guarantor that are not affiliated with the Lender, (b) was duly executed by the Company and the Guarantor, and (c) constitutes a legal, valid and binding obligation of the Company and the Guarantor. 

6. Full Force and Effect. Except as expressly modified by this Amendment, all of the terms, covenants, agreements, conditions and other provisions of
the Promissory Note shall remain in full force and effect in accordance with their respective terms. This Amendment shall not constitute an amendment or waiver of any provision of the Promissory Note except as expressly set forth herein. Upon the
execution and delivery hereof, the Promissory Note shall thereupon be deemed to be amended and supplemented as hereinabove set forth as fully and with the same effect as if the amendments and supplements made hereby were originally set forth in the
Promissory Note, and this Amendment and the Promissory Note shall henceforth be read, taken and construed as one and the same instrument, but such amendments and supplements shall not 

  
 - 2 - 

 
operate so as to render invalid or improper any action heretofore taken under the Promissory Note. As used in the Promissory Note, the terms “this Note,” “herein,”
“hereinafter,” “hereto,” and words of similar import shall mean and refer to, from and after the date of this Amendment, unless the context requires otherwise, the Promissory Note as amended by this Amendment. For the avoidance
of doubt, references to the phrases “the date of this Note” or “the date hereof”, wherever used in the Promissory Note, as amended by this Amendment, shall mean March 11, 2015. In the event of any inconsistency between this
Amendment and the Promissory Note with respect to the matters set forth herein, this Amendment shall take precedence. 
 7. Governing Law. This
Amendment, and all claims arising out of or relating to it, shall be governed by and construed in accordance with the laws of the State of New York, excluding that body of law relating to conflict of laws. 

8. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be enforceable against the parties actually
executing such counterparts, and all of which together shall constitute one instrument. 
 [remainder of page intentionally left blank]

  
 - 3 - 

 IN WITNESS WHEREOF, the Company, the Guarantor and the Lender have caused this Amendment
to be executed as of the day and year as first written above. 
  

			
	ODYSSEY MARINE ENTERPRISES, LTD.
		
	By:	 	 /s/ Mark D. Gordon

	Name:	 	Mark D. Gordon
	Title:	 	Vice President & Director
		
	Address:	 	
		 	
		 	
		 	
	
	ODYSSEY MARINE EXPLORATION, INC.
		
	By:	 	 /s/ Mark D. Gordon

	Name:	 	Mark D. Gordon
	Title:	 	President & CEO
		
	Address:	 	
		 	
		 	
		 	

  

			
	ACCEPTED AND AGREED TO:
	MINERA DEL NORTE, S.A. DE C.V.
		
	By:	 	 /s/ Andres Gonzales Saravaria

	Name:	 	Andres Gonzales Saravaria
	Title:	 	General Counsel and Attorney in Fact
		
	Address:EX-10.1

 Exhibit 10.1 
  

			
	 

	  	 Orexigen Therapeutics, Inc.

3344 North Torrey Pines Court
 Suite 200

La Jolla, CA 92037
 Phone: 858-875-8600

Fax 858-875-8650

	  	
	 	  	 www.orexigen.com

 

 September 30, 2015 

Mark Booth 
 c/o Orexigen
Therapeutics, Inc. 
 3344 N. Torrey Pines Court, Suite 200 

La Jolla, CA 92037 
  

	RE:      Separation	 and Consulting Agreement 

Dear Mark: 
 This letter sets
forth the terms of the separation and consulting agreement (this “Agreement”) that Orexigen Therapeutics, Inc. (the “Company”) is offering to you in connection with your voluntary resignation as an
officer and employee of the Company. 
 1.        Separation
Date.  You agree and acknowledge that your last day of employment with the Company and your employment resignation date will be effective September 30, 2015 (the “Separation Date”). As of the Separation
Date, you will no longer be employed as the Company’s Chief Commercial Officer, and you will no longer hold any other employment or officer positions with the Company. You further acknowledge and agree that the circumstances of your employment
resignation do not qualify as an “Involuntary Termination Without Cause” or a “Constructive Termination During a Change in Control Period” as defined in your February 22, 2010 Amended and Restated Employment Agreement with
the Company, as amended on February 15, 2013 (together, the “Employment Agreement”), or otherwise entitle you to any severance benefits. 

2.        Accrued Salary and Vacation.  No later than the Separation
Date, the Company will pay you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. You will receive these payments regardless of whether you enter into
this Agreement. 
 3.        Expenses.  You should submit, within
thirty (30) days after the Separation Date, expense reports to the Company seeking reimbursement for any business expenses incurred through the Separation Date. The Company will reimburse you for these business expenses, pursuant to its
standard policies and practices. Please submit your expense report to: Orexigen Therapeutics, Inc.; Attn: Finance, 3344 N. Torrey Pines Court, Suite 200, La Jolla, CA 92037. 

4.        Termination Benefits.  Although the Company is not
otherwise obligated to do so, if you timely sign, date and return this fully executed Agreement to the Company no later 

 Mark Booth 

September 30, 2015 
  Page
 2
 
  

 
than twenty-one (21) calendar days following the date of this Agreement and this Agreement, and the release of claims set forth in Section 14 below, becomes effective on the eighth day
following your timely execution of this Agreement (the “Effective Date”), the Company will provide you with the following termination benefits (the “Termination Benefits”): 

(a)        Continued Eligibility for 2015 Bonus.  You will remain
eligible for a pro-rated annual bonus for calendar year 2015 (the “Bonus”), which will be determined within the sole discretion of the Company’s Board of Directors (the “Board”), or an authorized
committee or officer of the Company, if so delegated by the Board. If the Board (or authorized committee or officer) approves a Bonus for you, such Bonus will be subject to standard payroll deductions and withholdings, and will be paid to you during
the 2016 calendar year at the same time that 2015 bonuses are paid to the Company’s other eligible executive employees (but in no event will the Bonus be paid to you later than March 15, 2016). 

(b)        Consulting Agreement.  The Company will agree to retain
you, and you will agree to make yourself available to perform services as a consultant under the terms of the Consulting Agreement attached hereto as Exhibit B. You must sign and return the Consulting Agreement no later than the date
that you return this fully signed Agreement. 
 5.        Health
Insurance.  To the extent provided by the federal COBRA law or, if applicable, state insurance laws (collectively, “COBRA”), and by the Company’s current group health insurance policies, you will be
eligible to continue your group health insurance benefits after the Separation Date. Later, you may be able to convert to an individual policy through the provider of the Company’s health insurance, if you wish, at your own expense. You will be
provided with a separate notice more specifically describing your rights and obligations to continuing health insurance coverage under COBRA on or after the Separation Date. 

6.        Equity. 

(a)        Although the terms of each of your outstanding stock options, as
set forth on Exhibit A hereto (the “Options”), provide that the Options will expire and cease to be exercisable three months following the termination of your services, you acknowledge and agree that the Options
will expire and cease to be exercisable on April 7, 2016 (the “Expiration Date”) and that, subject to Section 6(b), you may exercise on or before the Expiration Date any of the Options that were vested and
exercisable as of the Separation Date. 
 (b)        Notwithstanding
anything to the contrary in this Agreement, you acknowledge and agree that any portions of the Options that are unvested and unexercisable as of the Separation Date, will not become vested or exercisable, and you will receive no additional vesting
of such Options from and after the Separation Date, and all such portions of such Options will immediately expire and terminate as of such Separation Date. 

 Mark Booth 

September 30, 2015 
  Page
 3
 
  

 7.        No Other Compensation or
Benefits.  You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation, bonus, severance, or benefits before or after the Separation Date,
with the sole exception of any benefit the right to which has vested as of the Separation Date under the express terms of a Company benefit plan. 

8.        Return of Company Property.  You agree to immediately
return to the Company all Company documents (and all copies thereof) and other Company property which you have in your possession or control, including but not limited to any materials of any kind which contain or embody any proprietary or
confidential information of the Company (and all reproductions thereof in whole or in part). You also agree to immediately make a diligent search to locate any such documents, property and information. In addition, if you have used any personally
owned computer, server, e-mail system, mobile phone, or portable electronic device (e.g., BlackBerry, iPhone or iPad) (collectively, “Personal Systems”) to receive, store, prepare or transmit any Company
confidential or proprietary data, materials or information, then on or before the fifth day following the Separation Date, or earlier if requested, you will provide the Company with a computer-useable copy of all such information and then
permanently delete and expunge all such Company confidential or proprietary information from such Personal Systems without retaining any copy or reproduction in any form. You agree to provide the Company access to your Personal Systems, if
requested, for the purpose of verifying that the required copying and/or deletion is completed. The Company will provide you with access to its confidential and proprietary information or materials to the extent needed for you to perform your
consulting services. 
 9.        Proprietary Information
Obligations.   You agree to refrain from any use or disclosure of the Company’s confidential or proprietary information or materials. Additionally, you reaffirm your obligation to comply with the Proprietary Information and
Inventions Assignment Agreement (the “Proprietary Information and Inventions Assignment Agreement”) you previously signed (attached hereto as Exhibit C). 

10.        Mutual Nondisparagement.  You agree not to disparage the
Company, and the Company’s officers, directors, employees, shareholders, investors and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation, and the Company agrees to direct its
officers and directors not to disparage you in any manner likely to be harmful to your business, business reputation or personal reputation; provided that the parties may respond accurately and fully to any question, inquiry or request for
information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. 

11.        Confidentiality.  The provisions of this Agreement will be
held in strictest confidence by you and the Company and will not be publicized or disclosed in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement to your immediate family; (b) the parties may
disclose this Agreement in confidence to their respective attorneys, 

 Mark Booth 

September 30, 2015 
  Page
 4
 
  

 accountants, auditors, tax preparers, and financial advisors; (c) the Company may
disclose this Agreement as necessary to fulfill standard or legally required corporate reporting or disclosure requirements; and (d) the parties may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as
otherwise required by law. In particular, and without limitation, you agree not to disclose the terms of this Agreement to any current or former Company employee or affiliate. 

12.        Cooperation.  Through April 7, 2016, you agree to
voluntarily cooperate with the Company, if you have knowledge of facts relevant to any threatened or pending claim, investigation, audit or litigation against or by the Company, by making yourself reasonably available without further compensation
(except pursuant to the Consulting Agreement, and other than your preapproved, reasonable and documented expenses) for interviews with the Company or its legal counsel, for preparing for and providing deposition testimony, and for preparing for and
providing trial testimony. 
 13.        No Admissions.  Nothing
contained in this Agreement shall be construed as an admission by you or the Company of any liability, obligation, wrongdoing or violation of law. 

14.        Release of Claims.  

(a)        General Release.  In exchange for the consideration
provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company and its current and former directors, officers, employees, shareholders, investors, partners, agents,
attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) of and from any and all claims, liabilities and obligations, both known and
unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”). 

(b)        Scope of Release.  The Released Claims include, but are
not limited to: (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii) all claims related to your compensation or benefits from the Company, including salary,
bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (iii) all claims for breach of contract, wrongful termination, and breach of the
implied covenant of good faith and fair dealing (including but not limited to all claims for severance benefits under your Employment Agreement); (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in
violation of public policy; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as
amended), the federal Americans with Disabilities Act of 1990 (as amended), the federal Family and Medical Leave Act (as amended) (“FMLA”), the federal Age Discrimination in Employment Act of 1967 (as amended) (the
“ADEA”), the California Labor Code (as amended), the California 

 Mark Booth 

September 30, 2015 
  Page
 5
 
  

 Family Rights Act (“CFRA”), the California Fair Employment and
Housing Act (as amended), the Illinois Human Rights Act, the Illinois Equal Pay Act, the Illinois Whistleblower Act, the Cook County Human Rights Ordinance, and the Chicago Human Rights Ordinance. 

(c)        Excluded Claims.  Notwithstanding the foregoing,
the following are not included in the Released Claims (the “Excluded Claims”): (i) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to which you are
a party, the charter, bylaws, or operating agreements of the Company, or under applicable law; (ii) any rights which are not waivable as a matter of law; and (iii) any claims for breach of this Agreement. In addition, nothing in this
Agreement prevents you from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing, the Illinois Human Rights
Commission, or any other government agency, except that you acknowledge and agree that you are hereby waiving your right to any monetary benefits in connection with any such claim, charge or proceeding. You hereby represent and warrant that, other
than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims. 

(d)        ADEA Waiver.  You acknowledge that you are knowingly and
voluntarily waiving and releasing any rights you may have under the ADEA (the “ADEA Waiver”), and that the consideration given for this ADEA Waiver is in addition to anything of value to which you are already entitled. You
further acknowledge that you have been advised, as required by the ADEA, that: (i) your ADEA Waiver does not apply to any rights or claims that may arise after the date that you sign this Agreement; (ii) you should consult with an attorney
prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) calendar days to consider this Agreement (although you may choose voluntarily to sign it earlier); (iv) you have seven
(7) calendar days following the date you sign this Agreement to revoke the ADEA Waiver (by providing written notice of your revocation to the Company); and (v) this Agreement will not be effective until the date upon which the revocation
period has expired, which will be the Effective Date, provided that you do not revoke it prior to such date. 

(e)        Section 1542 Waiver.  In giving the releases set
forth in this Agreement, which include claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend
to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” You hereby expressly
waive and relinquish all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to the releases granted herein, including but not limited to the release of unknown and unsuspected
claims granted in this Agreement. 

 Mark Booth 

September 30, 2015 
  Page
 6
 
  

15.        Representations.  You hereby represent that you have been
paid all compensation owed for all time worked, you have received all the leave and leave benefits and protections for which you are eligible pursuant to the FMLA, CFRA or any applicable laws or Company policies, and you have not suffered any
work-related injury or illness for which you have not already filed a workers’ compensation claim. 

16.        Miscellaneous.  This Agreement, along with Exhibits A, B,
and C, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than
those expressly contained herein, and it supersedes any other such promises, warranties or representations (including but not limited to those in the Employment Agreement). This Agreement may not be modified or amended except in a written agreement
signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, and their heirs,
successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question shall be deemed
modified so as to be rendered enforceable in a manner consistent with the intent of the parties, insofar as possible under applicable law. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a
breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement shall be deemed to have been entered into, and shall be construed and enforced, in
accordance with the laws of the State of California without regard to conflicts of law principles. This Agreement may be executed in counterparts, each of which shall be deemed to be part of one original, and facsimile signatures and signatures
transmitted by PDF shall be equivalent to original signatures. 
 If this Agreement is acceptable to you, please sign and date it below
within twenty-one (21) calendar days of your receipt of this Agreement. If you do not sign and return it to the Company within the aforementioned timeframe, the Company’s offer to enter into this Agreement will expire (including the offer
to enter into the Consulting Agreement). 

 Mark Booth 

September 30, 2015 
  Page
 7
 
  

 We wish you the best in your future endeavors. 

Sincerely, 
 OREXIGEN
THERAPEUTICS, INC. 
  

			
		
	By:	 	/s/ Michael A. Narachi
		 	            Michael A. Narachi
		 	            President & Chief Executive Officer        

 Exhibit A – Option Grants 

Exhibit B – Consulting Agreement 
 Exhibit C –
Proprietary Information and Inventions Agreement 
 AGREED: 

 

							
	 /s/ Mark Booth
	 	                            	 	 September 30, 2015
	 	
	Mark Booth	 		 	Date	 	

 Mark Booth 

September 30, 2015 
  Page
 8
 
  

 EXHIBIT A 

OPTION GRANTS 
  

							
	  	 	
    Number of Shares    

Subject to
Option Grant
  
	 	 Number
of
Unvested Shares
  Underlying Option  
 as of
Separation Date

 
	 	
  Number of Vested and  
Outstanding Shares
Underlying Option as

of
 Separation Date

 

	 Stock Option granted
February 3, 2015
  
	 	88,925	 	75,957	 	12,968
	 Stock Option granted
February 7, 2014
  
	 	205,000	 	123,855	 	81,145
	
Stock Option granted
February 15, 2013

 
	 	190,000	 	67,292	 	122,708
	 Stock Option granted
January 25, 2012
  
	 	280,000	 	23,335	 	256,665
	 Stock Option granted
February 27, 2012
  
	 	70,000	 	7,292	 	62,708
	
Stock Option granted
July 25, 2011

 
	 	832,000	 	0	 	413,924

 EXHIBIT B 

Consulting Agreement 

 EXHIBIT C 

Proprietary Information and Inventions Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]